Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 3

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Jan 21, 2016; 22(3): 1224-1235
Published online Jan 21, 2016. doi: 10.3748/wjg.v22.i3.1224

Table 1 Genetic alterations of group II p21-activated kinases in gastrointestinal cancers

Cancer location	PAKs	Alteration		Ref.
Cancer location	PAKs	Gene ampliﬁcation	Gene or protein overexpression
Oesophagus	PAK4		√	Ref.	[86]
Gallbladder	PAK4		√	[44]
Liver	PAK4		√	[64]
	PAK5		√	[21]
	PAK6		√	[67]
Pancreas	PAK4	√	√	[16,32,45,46]
Stomach	PAK4		√	[48,79]
Stomach	PAK5		√	[20]
Colon	PAK4	√		[47]
	PAK5		√	[56]
	PAK6		√	[95]

PAKs: p21-activated kinases.

Citation: Shao YG, Ning K, Li F. Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer. World J Gastroenterol 2016; 22(3): 1224-1235
URL: https://www.wjgnet.com/1007-9327/full/v22/i3/1224.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i3.1224

Shao YG, Ning K, Li F. Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer. World J Gastroenterol 2016; 22(3): 1224-1235 [PMID: 26811660 DOI: 10.3748/wjg.v22.i3.1224]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.